PL4121419T3 - Kokryształy kwasu (1r,3s)-3-(5-cyjano-4-fenylo-1,3-tiazol-2-ilokarbamoilo)cyklopentanokarboksylowego - Google Patents
Kokryształy kwasu (1r,3s)-3-(5-cyjano-4-fenylo-1,3-tiazol-2-ilokarbamoilo)cyklopentanokarboksylowegoInfo
- Publication number
- PL4121419T3 PL4121419T3 PL21710531.1T PL21710531T PL4121419T3 PL 4121419 T3 PL4121419 T3 PL 4121419T3 PL 21710531 T PL21710531 T PL 21710531T PL 4121419 T3 PL4121419 T3 PL 4121419T3
- Authority
- PL
- Poland
- Prior art keywords
- cocrystals
- ylcarbamoyl
- thiazol
- cyano
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/02—Salts; Complexes; Addition compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382194.7A EP3882240A1 (en) | 2020-03-16 | 2020-03-16 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
| PCT/EP2021/056506 WO2021185748A1 (en) | 2020-03-16 | 2021-03-15 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4121419T3 true PL4121419T3 (pl) | 2025-02-17 |
Family
ID=69953938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21710531.1T PL4121419T3 (pl) | 2020-03-16 | 2021-03-15 | Kokryształy kwasu (1r,3s)-3-(5-cyjano-4-fenylo-1,3-tiazol-2-ilokarbamoilo)cyklopentanokarboksylowego |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12384754B2 (https=) |
| EP (2) | EP3882240A1 (https=) |
| JP (1) | JP7779846B2 (https=) |
| KR (1) | KR20220154791A (https=) |
| CN (1) | CN115298169B (https=) |
| AU (1) | AU2021237686B2 (https=) |
| BR (1) | BR112022018449A2 (https=) |
| CA (1) | CA3171894C (https=) |
| DK (1) | DK4121419T3 (https=) |
| ES (1) | ES3002084T3 (https=) |
| FI (1) | FI4121419T3 (https=) |
| HR (1) | HRP20241515T1 (https=) |
| HU (1) | HUE068886T2 (https=) |
| LT (1) | LT4121419T (https=) |
| MX (1) | MX2022011530A (https=) |
| PL (1) | PL4121419T3 (https=) |
| PT (1) | PT4121419T (https=) |
| RS (1) | RS66214B1 (https=) |
| SI (1) | SI4121419T1 (https=) |
| WO (1) | WO2021185748A1 (https=) |
| ZA (1) | ZA202211247B (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2331220B1 (es) | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| US8779146B2 (en) | 2010-04-28 | 2014-07-15 | Nuformix Limited | Cilostazol cocrystals and compositions |
| LT3592734T (lt) | 2017-03-06 | 2021-07-26 | Palobiofarma, S.L. | (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska |
-
2020
- 2020-03-16 EP EP20382194.7A patent/EP3882240A1/en not_active Withdrawn
-
2021
- 2021-03-15 CN CN202180021708.3A patent/CN115298169B/zh active Active
- 2021-03-15 EP EP21710531.1A patent/EP4121419B1/en active Active
- 2021-03-15 PT PT217105311T patent/PT4121419T/pt unknown
- 2021-03-15 MX MX2022011530A patent/MX2022011530A/es unknown
- 2021-03-15 HR HRP20241515TT patent/HRP20241515T1/hr unknown
- 2021-03-15 ES ES21710531T patent/ES3002084T3/es active Active
- 2021-03-15 AU AU2021237686A patent/AU2021237686B2/en active Active
- 2021-03-15 BR BR112022018449A patent/BR112022018449A2/pt unknown
- 2021-03-15 RS RS20241203A patent/RS66214B1/sr unknown
- 2021-03-15 CA CA3171894A patent/CA3171894C/en active Active
- 2021-03-15 HU HUE21710531A patent/HUE068886T2/hu unknown
- 2021-03-15 WO PCT/EP2021/056506 patent/WO2021185748A1/en not_active Ceased
- 2021-03-15 DK DK21710531.1T patent/DK4121419T3/da active
- 2021-03-15 US US17/906,367 patent/US12384754B2/en active Active
- 2021-03-15 KR KR1020227035871A patent/KR20220154791A/ko active Pending
- 2021-03-15 LT LTEPPCT/EP2021/056506T patent/LT4121419T/lt unknown
- 2021-03-15 SI SI202130224T patent/SI4121419T1/sl unknown
- 2021-03-15 PL PL21710531.1T patent/PL4121419T3/pl unknown
- 2021-03-15 FI FIEP21710531.1T patent/FI4121419T3/fi active
- 2021-03-15 JP JP2022555805A patent/JP7779846B2/ja active Active
-
2022
- 2022-10-13 ZA ZA2022/11247A patent/ZA202211247B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3002084T3 (en) | 2025-03-06 |
| JP7779846B2 (ja) | 2025-12-03 |
| KR20220154791A (ko) | 2022-11-22 |
| MX2022011530A (es) | 2022-10-13 |
| HUE068886T2 (hu) | 2025-02-28 |
| EP4121419A1 (en) | 2023-01-25 |
| CN115298169A (zh) | 2022-11-04 |
| FI4121419T3 (fi) | 2024-11-04 |
| US12384754B2 (en) | 2025-08-12 |
| LT4121419T (lt) | 2024-11-25 |
| CA3171894C (en) | 2025-03-11 |
| EP3882240A1 (en) | 2021-09-22 |
| WO2021185748A1 (en) | 2021-09-23 |
| CN115298169B (zh) | 2024-11-19 |
| US20230183195A1 (en) | 2023-06-15 |
| DK4121419T3 (da) | 2024-10-28 |
| ZA202211247B (en) | 2023-12-20 |
| AU2021237686A1 (en) | 2022-10-06 |
| BR112022018449A2 (pt) | 2022-11-01 |
| AU2021237686B2 (en) | 2026-04-09 |
| HRP20241515T1 (hr) | 2025-01-03 |
| CA3171894A1 (en) | 2021-09-23 |
| EP4121419B1 (en) | 2024-08-14 |
| PT4121419T (pt) | 2024-11-18 |
| SI4121419T1 (sl) | 2025-02-28 |
| RS66214B1 (sr) | 2024-12-31 |
| JP2023517722A (ja) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4003950A4 (en) | C4 ALKANOIC ACID RECYCLING CONTENT | |
| EP3956783A4 (en) | MONETIZATION OF ANIMAL DATA | |
| WO2016012965A3 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| EP3891620A4 (en) | TRANSACTIONAL STREAMING OF CHANGE TRACKING DATA | |
| WO2017042828A3 (en) | Process for the preparation of selexipag | |
| EP4212503A4 (en) | FLUORINATED CARBOXYLIC ACID SALT COMPOUND | |
| ZA202211247B (en) | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | |
| HK40087530A (en) | Cocrystals of(1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid | |
| EP3987772A4 (en) | SHARED RESOURCE FOR TRANSFORMING DATA | |
| SMT202100419T1 (it) | Sale amminico dell'acido (1r, 3s)-3-(5-ciano-4-fenil-1, 3-tiazol-2-ilcarbammoil)ciclopentan carbossilico | |
| EP4059944A4 (en) | METHOD FOR PREPARING AN OLIGONUCLICE ACID COMPOUND | |
| EP4059943A4 (en) | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | |
| SI3980003T1 (sl) | Izopropil ester (((1R,2S,5R)-2-izopropil-5-metil-cikloheksankarbonil)- amino)-ocetne kisline za zdravljenje kroničnega kašlja | |
| EP4064827A4 (en) | TRANSFORMATION PROCESS | |
| EP4083224A4 (en) | METHOD FOR ASYMMETRIC TARGET NUCLEIC ACID AMPLIFICATION | |
| EP3976110A4 (en) | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | |
| IL290505A (en) | Process for the preparation of carboxylic acid derivatives of 3-bromo-4,5-dihydro-1h-pyrazoles | |
| EP3093281A4 (en) | Alkali metal salt of perfluoro(vinyloxy polyether) carboxylic acid, and method for producing same | |
| HK40128362A (en) | Metap2 inhibitors for the treatment of pulmonary fibrosis | |
| CA3264343A1 (en) | METAP2 INHIBITORS FOR THE TREATMENT OF PULMONARY FIBROSIS | |
| EP4319743A4 (en) | UPADACITINIB CO-CRYSTALS | |
| HK40116338A (en) | Crystalline forms of n-((1r,3s)-3-(4-acetylpiperazin-1-yl)cyclohexyl)-4-fluoro-7-methyl-1h-indole-2-carboxamide | |
| CA3287358A1 (en) | Formation of co-crystals | |
| HK40073337A (en) | Glycolate oxidase inhibitors for the treatment of disease | |
| HK40058379A (en) | Methods of promoting remyelination |